Alvotech and teva announce u.s. approval of simlandi® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to humira®

Reykjavik, iceland and parsippany, n.j., feb. 24, 2024 (globe newswire) -- alvotech (nasdaq: alvo) and teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that the u.s. food and drug administration (fda) has approved simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. in 2023, humira was one of the highest-grossing pharmaceutical products in the world, with sales in the u.s. of nearly $12.2 billion[ 1]. teva is alvotech's strategic partner for the exclusive commercialization of simlandi in the united states.
ALVO Ratings Summary
ALVO Quant Ranking